|
Are you curious about the new diet drug Acomplia? Acomplia is the brand name that refers to the drug Rimonabant, an anorectic anti-obesity drug.
Acomplia was developed by the European company Sanofi-Aventis, and as of yet is still in the experimental stages.
Termed as a CB1 cannabinoid receptor antagonist, Acomplia essentially works as an appetite suppressant. However it is the first cannabinoid receptor antagonist to be approved for sale anywhere in the world and is currently only available in the United Kingdom and Denmark yet many other European nations are considering its approval and it is being considered by the Food and Drug Association in the United States.
The drug is recommended for use in conjunction with a balanced and regulated diet and an organized exercise routine. It is also suggested that this drug is a helpful weight loss aid for those at risk of developing or those who are already suffering from dyslipidaeamia and type 2 diabetes. Rimonabant has also been toted as an effective anti-smoking drug as it is supposed to suppress the body's cravings for tobacco.
While studies stretching over a two-year period determined that approximately one-third of the patients lost about 10% of their body weight, there have been suggestions of several negative side effects. As this drug impacts the central nervous system, it tends to influence the individual's mood. In fact some individuals taking the drug have been said to suffer from depression, anxiety, nausea and irritability. In this it is important to remember that true long term effects of the drug have yet to be determined and thus it is recommended that you consult your doctor and thefitmap.com for more information!
|
